AU2005207925B2 - Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase Type 1 - Google Patents

Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase Type 1 Download PDF

Info

Publication number
AU2005207925B2
AU2005207925B2 AU2005207925A AU2005207925A AU2005207925B2 AU 2005207925 B2 AU2005207925 B2 AU 2005207925B2 AU 2005207925 A AU2005207925 A AU 2005207925A AU 2005207925 A AU2005207925 A AU 2005207925A AU 2005207925 B2 AU2005207925 B2 AU 2005207925B2
Authority
AU
Australia
Prior art keywords
crystalline
anhydrate
monohydrate
solid
magnetic resonance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005207925A
Other languages
English (en)
Other versions
AU2005207925A1 (en
Inventor
Yuri Bereznitski
Mark A. Huffman
Joseph E. Lynch
Matthew Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2005207925A1 publication Critical patent/AU2005207925A1/en
Application granted granted Critical
Publication of AU2005207925B2 publication Critical patent/AU2005207925B2/en
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Request to Amend Deed and Register Assignors: MERCK & CO., INC.
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Request to Amend Deed and Register Assignors: MERCK & CO., INC.
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Request to Amend Deed and Register Assignors: MERCK SHARP & DOHME CORP.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2005207925A 2004-01-26 2005-01-21 Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase Type 1 Ceased AU2005207925B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53920604P 2004-01-26 2004-01-26
US60/539,206 2004-01-26
PCT/US2005/001928 WO2005073200A1 (en) 2004-01-26 2005-01-21 Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1

Publications (2)

Publication Number Publication Date
AU2005207925A1 AU2005207925A1 (en) 2005-08-11
AU2005207925B2 true AU2005207925B2 (en) 2008-09-04

Family

ID=34826043

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005207925A Ceased AU2005207925B2 (en) 2004-01-26 2005-01-21 Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase Type 1

Country Status (8)

Country Link
US (1) US7875642B2 (enExample)
EP (1) EP1711477A4 (enExample)
JP (1) JP2007519726A (enExample)
CN (1) CN1910161A (enExample)
AU (1) AU2005207925B2 (enExample)
CA (1) CA2553345C (enExample)
IN (1) IN2012DN03023A (enExample)
WO (1) WO2005073200A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105127A2 (en) 2005-03-31 2006-10-05 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2007038452A1 (en) * 2005-09-28 2007-04-05 Merck & Co., Inc. Process for synthesizing 1,2,4-triazoles
CA2636826C (en) 2006-01-18 2011-11-29 F.Hoffmann-La Roche Ag Thiazoles as 11 beta-hsd1 inhibitors
JP2009526059A (ja) 2006-02-07 2009-07-16 ワイス １１−ベータｈｓｄ１阻害剤
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2012041013A1 (en) * 2010-10-01 2012-04-05 Shan Dong Luye Pharmaceutical Co., Ltd. Polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods for preparing the same and use of the same
SG11201908181XA (en) 2017-03-06 2019-10-30 Venatorx Pharmaceuticals Inc Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003104207A2 (en) * 2002-06-10 2003-12-18 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0100860A3 (en) 1997-12-11 2003-03-28 Janssen Pharmaceutica Nv Retinoic acid mimetic anilides, process for their preparation and pharmaceutical compositions containing them
US20030073850A1 (en) 1998-08-07 2003-04-17 Altenbach Robert J. 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use
US6503935B1 (en) 1998-08-07 2003-01-07 Abbott Laboratories Imidazoles and related compounds as α1A agonists
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
WO2003004497A1 (en) 2001-07-05 2003-01-16 Sumitomo Pharmaceuticals Company, Limited Novel heterocyclic compound
DE60317631T2 (de) * 2002-02-01 2008-09-25 Merck & Co., Inc. 11-beta-hydroxysteroid-dehydrogenase-1-hemmer zur behandlung von diabetes, adipositas und dyslipidämie

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003104207A2 (en) * 2002-06-10 2003-12-18 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia

Also Published As

Publication number Publication date
WO2005073200A1 (en) 2005-08-11
US20090186928A1 (en) 2009-07-23
CA2553345C (en) 2011-11-15
CA2553345A1 (en) 2005-08-11
IN2012DN03023A (enExample) 2015-07-31
US7875642B2 (en) 2011-01-25
AU2005207925A1 (en) 2005-08-11
JP2007519726A (ja) 2007-07-19
EP1711477A1 (en) 2006-10-18
EP1711477A4 (en) 2009-06-10
CN1910161A (zh) 2007-02-07

Similar Documents

Publication Publication Date Title
JP3145410B2 (ja) 新規な４，６−ジアリールピリミジン誘導体及びその塩
US12421249B2 (en) Inhibitors of APOL1 and methods of using same
US20090264473A1 (en) Novel Crystalline Forms of Antidiabetic Compounds
US20080269499A1 (en) Crystalline forms and process for preparing spiro-hydantoin compounds
WO2009014676A1 (en) Novel crystalline form of a dihydrochloride salt of a dipeptidyl peptidase-iv inhibitor
US20250243223A1 (en) Solid state forms of ixazomib citrate
AU2005207925B2 (en) Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase Type 1
KR0162637B1 (ko) 단백질 키나아제 c 억제제로서 유용한 신규 퀴놀릴옥사졸-2-온
US20100056580A1 (en) Novel crystalline salt form of an antidiabetic compound
CA3178470A1 (en) Modulators of alpha-1 antitrypsin
HUT64759A (en) Method for producing tetrazolyl-(phenoxy-and phenoxy-alkyl-)-pyridinyl-pyridazines
TWI802654B (zh) 一種酮基吡啶醯胺類衍生物的晶型及其製備方法
AU2009324810B2 (en) Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1
EP1858844A1 (en) Novel crystalline forms of antidiabetic compounds
EP0553218A1 (en) Indole derivatives
EP0761656B1 (en) Alternate crystal form of tazofelone ((+,-)-5-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methyl)-4-thiazolidinone)
US6063799A (en) Alternate crystal form of Tazofelone
JP2000290280A (ja) フェニルアゾール化合物、製造法及び抗高脂血症薬
HK40025351B (en) Crystal form of oxopicolinamide derivative and preparation method therefor
HU211665A9 (hu) Az átmeneti oltalom az 1-19. igénypontokra vonatkozik.
HK1013822A (en) Alternate crystal form of tazofelone ((+,-)-5-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methyl)-4-thiazolidinone)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PATENTEE NAME FROM MERCK & CO., INC. TO MERCK SHARP & DOHME CORP.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired